Dr. Rajeshwar Motheram, Ph.D. has been Vice President of Pharmaceutical Development of SCYNEXIS, Inc. since October 1, 2015. Dr. Motheram responsible for pharmaceutical research and development, including chemistry, manufacturing and controls (CMC) and regulatory CMC strategy for SCYNEXIS' lead clinical asset, SCY-078, in Phase 2 development for the treatment of invasive fungal infections. Dr. Motheram joined SCYNEXIS with almost 20 years of experience in pharmaceutical research and development. Prior to joining SCYNEXIS, he held various senior positions at The Medicines Company, served as Vice President, Pharmaceutical Development. Prior to that, he held positions with Bristol-Myers Squibb Company, DuPont Pharmaceuticals Company and Baxter Pharmaceutical Products. He is a member of the American Association of Pharmaceutical Scientists. Dr. Motheram has a Ph.D. in Pharmaceutics from the University of the Sciences, Philadelphia College of Pharmacy and a Master of Science from the University of Mississippi.